On June 25, 2026, the U.S. Supreme Court issued one of the most consequential mass tort rulings in a generation. In Monsanto v. Durnell lawsuit (No. 24-1068), a 7-2 majority held that federal pesticide law expressly bars state-law failure-to-warn claims whenever a manufacturer complies with an EPA-approved label. The decision reversed a $1.25 million Missouri jury verdict against Monsanto and immediately reshaped the legal landscape for more than 60,000 pending Roundup-related claims. For plaintiffs across pesticide, pharmaceutical, and medical device litigation, understanding exactly what Durnell did — and did not — do is now essential to protecting any remaining legal rights.
What the Supreme Court Actually Decided in Monsanto v. Durnell
The Monsanto v. Durnell lawsuit reached the Supreme Court after a circuit split between Missouri and California courts created irreconcilable outcomes for similarly situated Roundup plaintiffs. The Court granted certiorari on January 16, 2026, limiting review to a single question: whether the Federal Insecticide, Fungicide, and Rodenticide Act’s express preemption clause, 7 U.S.C. §136v(b), bars state-law failure-to-warn claims that would impose labeling requirements beyond or different from those EPA approved. After oral argument on April 27, 2026, the Court answered with a definitive yes.
Writing for the majority, Justice Kavanaugh was joined by an ideologically diverse coalition: Chief Justice Roberts, Justices Thomas, Alito, Sotomayor, Kagan, and Barrett. Justices Jackson and Gorsuch dissented. The majority held that state tort duties — including common-law failure-to-warn duties — constitute “requirements” under FIFRA’s preemption clause just as formal state labeling statutes would. Because the EPA had repeatedly concluded that glyphosate is not carcinogenic and had approved Roundup’s label without a cancer warning, the Court found it “bizarre” to expose Monsanto to state tort liability for doing precisely what federal regulators required. The opinion reversed the Missouri Court of Appeals and vacated John Durnell’s $1.25 million compensatory damages award.
Justice Thomas wrote separately to emphasize that the holding flows naturally from the Court’s prior preemption doctrine established in Riegel v. Medtronic (medical devices) and Buckman Co. v. Plaintiffs’ Legal Committee, framing Durnell as a logical extension of a consistent line of federal supremacy principles in product regulation cases.
Who Wins and Who Loses: The Immediate Impact on Mass Tort Litigation
The most direct losers in the Monsanto v. Durnell lawsuit ruling are the estimated 60,000-plus individuals with pending Roundup-related claims whose primary legal theory was failure to warn about glyphosate’s alleged cancer risks. For those plaintiffs, the ruling effectively eliminates the claim that carried the most trial success in prior years. Bayer AG, which acquired Monsanto, had sought Supreme Court review of Roundup verdicts for years; Durnell finally delivered the favorable ruling expected to save the company billions in exposure across thousands of pending cases.
| Litigation Category | Key Federal Law | Failure-to-Warn Claims After Durnell | Estimated Pending Claims (2026) |
|---|---|---|---|
| Roundup / Glyphosate | FIFRA (7 U.S.C. §136v) | Expressly Preempted | 60,000+ (Cornell LII) |
| Pharmaceutical Drugs (e.g., Depo-Provera) | FDCA / Wyeth v. Levine | Largely Intact — No Express Preemption | Tens of thousands |
| Medical Devices — Class III (PMA) | MDA / Riegel v. Medtronic | Preempted under MDA, not Durnell | Varies by MDL |
| Medical Devices — 510(k) (e.g., Bard PowerPort) | MDA 510(k) pathway | Not Preempted by Durnell or MDA express clause | Thousands |
| NEC Baby Formula | No FIFRA; not EPA-regulated | Not Preempted — Durnell Distinguished | Active MDL |
The decision’s reach does not stop at Roundup. Courts and litigants are already watching how Durnell might be invoked beyond pesticides. Within days of the ruling, an Illinois federal judge in the NEC baby formula MDL cited the Monsanto v. Durnell lawsuit decision in rulings on Mead Johnson’s motions to dismiss — though plaintiffs successfully argued, and the judge agreed, that cow’s milk-based infant formula is not an EPA-regulated pesticide under FIFRA, making Durnell inapplicable in that context.
What Durnell Does NOT Affect: Drug, Device, and Other Mass Torts
For plaintiffs in pharmaceutical failure-to-warn MDLs, the Monsanto v. Durnell lawsuit decision functions as a legal near-miss. The majority opinion explicitly distinguished Wyeth v. Levine (2009), which remains controlling law for FDA-regulated prescription drugs. Unlike FIFRA, the Federal Food, Drug, and Cosmetic Act contains no comparable express preemption clause for labeling, meaning that drug manufacturers can still face state-law failure-to-warn liability even when they comply with FDA-approved labeling. The Depo-Provera MDL, for example, moves forward on its existing track — Pfizer’s Daubert hearing is scheduled for September 18, 2026, entirely under FDCA standards, completely unaffected by Durnell.
Medical device litigation presents a more layered picture. Class III devices approved through the Premarket Approval (PMA) pathway have long faced express preemption under the Medical Device Amendments, as established in Riegel v. Medtronic — a doctrine Justice Thomas noted in his concurrence as a close analogue to Durnell. However, devices cleared through the 510(k) substantial equivalence pathway, such as the Bard PowerPort, do not carry the same express preemption clause, and failure-to-warn claims in those MDLs remain viable. If you have suffered harm from a defective drug or device, a medical malpractice calculator can help you understand the potential value of your injury claim under applicable law.
How Roundup Plaintiffs Must Adapt Their Legal Strategy Now
The Monsanto v. Durnell lawsuit ruling does not make all Roundup claims disappear — but it forces a dramatic strategic pivot. With failure-to-warn theories now expressly preempted under FIFRA, plaintiffs’ attorneys are examining whether viable alternative theories exist. The primary candidates are design defect claims and negligent manufacturing claims, both of which are grounded in the product’s composition or production rather than its labeling. However, legal analysts note that such claims face significantly higher evidentiary burdens in Roundup litigation specifically, given glyphosate’s approved chemical profile and widespread regulatory endorsement by the EPA.
Plaintiffs pursuing design defect theories must show that Roundup was unreasonably dangerous as designed — a claim complicated by the EPA’s repeated determinations that glyphosate is not carcinogenic. Manufacturing defect theories require proof that a specific batch or production run deviated from intended specifications, which is difficult to establish in cases involving a standardized herbicide compound. Mass tort plaintiffs who suffered serious injury and are evaluating their remaining legal options should use a personal injury settlement calculator to get a baseline estimate of compensatory damages while consulting with counsel about which non-labeling theories remain viable in their jurisdiction. In cases where Roundup exposure allegedly contributed to a death, families should understand that wrongful death claims built on non-labeling theories may still proceed; a wrongful death calculator can help surviving family members assess potential damages. The strategic window for pivoting claims is narrow — lower courts are already applying Durnell aggressively, and plaintiffs who delay risk dismissal without an opportunity to replead.
The Broader Preemption Landscape After Durnell: What Comes Next
The Monsanto v. Durnell lawsuit decision signals that the Roberts Court is willing to give express preemption clauses their broadest natural reading when federal agencies have affirmatively approved the conduct at issue. Legal scholars and practitioners are already debating whether this interpretive approach will migrate into adjacent regulatory fields. The FDCA’s implied conflict preemption doctrine, the MDA’s express clause for PMA devices, and even certain CPSC-regulated product categories are being re-examined in light of Durnell’s reasoning. The October 2026 term is now open, and several petitions raising analogous preemption questions in drug and device cases are pending before the Court.
For mass tort plaintiffs and their counsel, the immediate lesson from the Monsanto v. Durnell lawsuit is this: identify your regulatory framework before your theory. FIFRA-regulated products now carry a near-complete federal shield for labeling-based claims. FDCA-regulated drugs remain exposed to state failure-to-warn liability under Wyeth. Medical devices require a device-by-device analysis of the approval pathway. And products that sit outside EPA or FDA jurisdiction — like the infant formula at issue in the NEC MDL — face no preemption bar from Durnell at all. The law of federal preemption in mass tort has never been more critical to understand, and the Cornell Legal Information Institute’s preemption overview provides a foundational reference for understanding how these doctrines interact across regulatory categories.
Frequently Asked Questions About Monsanto v. Durnell
Does the Monsanto v. Durnell lawsuit ruling mean all Roundup lawsuits are dismissed?
Not automatically. The June 25, 2026 ruling expressly preempts state-law failure-to-warn claims under FIFRA, which was the dominant theory in most Roundup litigation. However, plaintiffs may attempt to pursue alternative theories such as design defect or manufacturing defect, which are not based on labeling and are therefore not directly preempted by the Monsanto v. Durnell lawsuit holding. Those claims face a much higher evidentiary bar, but they are not categorically barred. Each pending case will need to be evaluated individually by counsel to determine whether a non-labeling theory is viable on its specific facts.
Does the Durnell ruling affect Depo-Provera, NEC formula, or other active MDLs?
For most active MDLs, the answer is no. The Monsanto v. Durnell lawsuit ruling applies only to products regulated under FIFRA — specifically, EPA-approved pesticide labels. The Depo-Provera MDL is governed by the FDCA and Wyeth v. Levine standards, which preserve state failure-to-warn claims for drugs, and its proceedings continue unaffected. The NEC baby formula MDL similarly survived a Durnell-based preemption argument because infant formula is not an EPA-regulated pesticide. Bard PowerPort and similar 510(k) medical device cases also remain unaffected because the MDA’s 510(k) pathway does not carry the same express preemption clause that FIFRA does.
Who were the justices who dissented in Monsanto v. Durnell, and why?
Justices Ketanji Brown Jackson and Neil Gorsuch dissented from the 7-2 majority in the Monsanto v. Durnell lawsuit. While the full text of dissents reflects each justice’s individual reasoning, the dissenting position generally objects to treating common-law tort duties as state “labeling requirements” subject to FIFRA’s express preemption clause, arguing that this interpretation dramatically expands federal preemption at the expense of state tort remedies that have historically served as a check on corporate conduct. The dissent signals a concern that the ruling removes meaningful accountability for manufacturers whose products may cause harm that federal regulators have not fully addressed.
Can plaintiffs still recover compensation for Roundup-related cancer injuries after Durnell?
Potentially, but the path is significantly narrower. The Monsanto v. Durnell lawsuit decision eliminates the failure-to-warn theory that produced the largest verdicts in prior trials. Remaining options — design defect and manufacturing defect claims — require plaintiffs to prove that Roundup was inherently flawed in its design or that a specific production batch deviated from specifications, burdens that are considerably harder to meet given the EPA’s longstanding conclusion that glyphosate is not carcinogenic. Plaintiffs with serious cancer diagnoses linked to Roundup exposure should consult qualified legal counsel immediately to assess whether any viable non-labeling theory can be advanced in their jurisdiction before lower courts finalize their application of Durnell.
What does FIFRA preemption mean, and why does it matter for mass tort plaintiffs?
FIFRA, the Federal Insecticide, Fungicide, and Rodenticide Act, contains an express preemption clause at 7 U.S.C. §136v(b) that prohibits states from imposing labeling requirements “in addition to or different from” those required under the federal statute. The Monsanto v. Durnell lawsuit ruling holds that state common-law tort duties — including jury verdicts that effectively require a different warning — constitute such “requirements” for preemption purposes. This matters enormously for mass tort plaintiffs because it means the entire failure-to-warn litigation framework that generated billions in verdicts against Monsanto over prior years is now federally barred for FIFRA-regulated products. Understanding which federal regulatory scheme governs your product is now the threshold question in any mass tort failure-to-warn case.
Legal Disclaimer: The content on this page is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction for guidance specific to your individual legal situation.
Related reading: Surgical Stapler Malfunction Injury Damages Calculator 2026: Liability When Misfires Cause Internal Bleeding, Sepsis & Permanent Ostomy
Related reading: The Feres Doctrine And Wrongful Death Damages: The 1950 Rule That Erases Every Damage Input When A Servicemember Dies In Uniform
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.